text:
While at the most recent Show Stoppers event, I had the opportunity to check out the LifeProof case for iPhone 4S (and iPhone 4). Protection is always key for any of our beloved electronics, and whether you are a mountain biker, a swim lover, or a karate king trying to keep your iPhone protected while doing your favorite event is a struggle -- until you meet LifeProof. The folks at LifeProof have spent a lot of time (over two years) designing this case, and a whole lot of money (over two million dollars) into making sure that their product was the best to hit the market.
Whether in rain, snow, ice, dirt, sand, or any other horrid condition you can think of with your device the folks at LifeProof know that their case can protect your device without you needing to take any additional precautions. So, does the case really hold up to its name? Let's take a look at some video action and check out some more images of the case on the device.
Pretty impressive stuff, huh? Not just everyday would you trust a case enough to just toss it in a tank of water, or drop it from six feet onto the ground without cringing in fear of what damage was just done to the device. We know, you understand that it can keep the device protected, but you want to know how much bulk it adds to your device, and if it is comfortable in the hand, right? Well, short answer, yes -- and let's take a look at why.
Personally I always fear the super protective cases because I know you need to add bulk to protect, and often times companies love to go overboard with the bulk, and it makes holding the device feel unnatural, and it no longer comfortably fits in your hand and pocket, but this case is different, very different. Adding only 1/16 of an inch, or 1.5mm, and adding less than an ounce of weight, to say the case is surprisingly small would be an understatement.
Featuring a two piece snap together design the case fits very snug over the device, making getting the case on and off a bit of a struggle, but that is their intentions for the waterproof seal that the case offers. The top piece includes an attached scratch resistant and waterproof screen protector that still allows for complete operation of the touch screen, and with the waterproof seal around the edge of the case you don't have to worry about any dirt or dust getting under there.
The headphone jack is sealed by a screw in cap that can be removed and they include a headphone extension that screws in for those of us who wish to use their headphones will keeping the device protected. The charging port is covered by a flip down piece that seals very tightly. The cut out will allow chargers to be plugged in to the device without the removal of the case, and LifeProof also offers a dock extender that plugs into the charging port and allows the device to be docked with the case on.
Overall the case does an extremely good job at protecting the device while adding minimal bulk to the slim profile of your iPhone 4S (or iPhone 4). The look of the case is quite plain, but they do offer a few different color selections such as black, white, pink, and purple, and the color covers the complete device, including the front so you can make it appear as though you have a totally different color iPhone than you really do!
We are giving away our review unit; it was used slightly (don't worry it isn't the one in the test video!) and it is in near perfect condition. Simply leave a comment letting us know what kind of abuse you put your iPhone through that requires LifeProof to protect it.
More: LifeProof
Jared started off writing about mobile phones back when BlackBerry ruled the market, and Windows Mobile was kinda cool. Now, with a family, mortgage and other responsibilities he has no choice but to look for the best deals, and he's here to share them with you.
Most Popular
By Tammy Rogers


text:
Church likely to face another harsh year, report says.
DUBLIN, April 9 (CDN) — Christian human rights activist Gao Zhisheng, kidnapped by state security agents on Feb. 4, 2009, has been released, though he appears unable to move or speak freely.
On Tuesday (April 6) Gao told Bob Fu, president of the U.S.-based China Aid Association (CAA), by telephone that he had just returned to his Beijing apartment from his guarded location in Shanxi Province.
"Gao Zhisheng and his family have suffered deeply from the long separation," Fu stated on CAA's website. "Despite the persecution, he continues to trust the Lord."
On Jan. 9, 2009, less than a month before Gao was abducted in his home village in Shaanxi Province, his family members began their escape from China. His wife, Geng He, along with then 16-year-old daughter Geng Ge and then 5-year-old son Gao Tianyu, arrived on foot to Thailand and eventually reached New York City on March 14, 2009.
With Fu and with reporters from The Associated Press (AP) this week, Gao declined to discuss his physical condition or how he was treated during his captivity. He told the AP that by leaving his role as a critic of human rights violations in China, he hopes to be re-united with his family.
"Gao is still not able to speak or move freely," Fu said on the CAA website. "We urge the Chinese government now to allow Gao Zhisheng to be reunited with his family. It is his right, according the Chinese law, to be able to see them, since he has broken no laws during his time of probation."
Gao's disappearance had drawn protests from international human rights groups, U.S. and British officials and the United Nations. He had defended house church Christians and coal miners as well as members of the banned Falun Gong, which fuses Buddhist-inspired teachings with forms of meditation. In 1999 Beijing banned it as an "evil cult."
Early in 2009, Gao authorized CAA to release his account of 50 days of torture by state-sponsored thugs in September and October of 2007. Gao had written the account in November 2007 while under house arrest in Beijing after prolonged beatings and electric shocks on his mouth and genitals.
Gao's suffering in the fall of 2007 followed an open letter he wrote to the U.S. Congress describing China's torture of Falun Gong members and other human rights abuses.
Another Harsh Year Expected
Chinese Christians can expect more attacks on large urban churches, more harsh punishments for house church leaders and tighter control of registered churches this year, according to CAA.
In a report summarizing persecution it monitored in 2009, CAA identified five key trends in China's management of Protestant Christianity.
Authorities last year specifically targeted house church leaders, sometimes handing out harsh sentences and fines; carried out violent raids on large urban churches; attempted to disrupt regular worship meetings and tightened control of churches registered with the government-approved Three-Self Protestant Movement (TSPM).
In response, some urban churches engaged in a "power encounter" with local governments, refusing to quietly allow officials to close or destroy their meeting places, CAA noted. For example, almost 1,000 members of Beijing Shouwang church on Nov. 1 worshiped in Haidian Park during a snowstorm after officials pressured Huajie Plaza managers not to renew the church rental contract.
These trends were confirmed by a Chinese House Church Alliance (CHCA) report, released in December, which described harassment and arrest of church leaders, violent raids on house churches and the oppression of TSPM churches.
While CAA reported only 77 incidents in 2009, these occurred throughout China, giving a broad indication of the status of Protestant Christians, particularly those in unregistered churches. A total of 2,935 people were affected in these incidents, a 44.8 percent increase from 2008. Of these, 389 were arrested, a decrease in arrests of 49 percent; and 23 were sentenced to prison, a decline of 34 percent.
Of the 389 people arrested, 211 were church leaders. Several received harsh prison sentences and fines, including Beijing bookstore owner and church leader Shi Weihan, who on June 12 was sentenced to three years in prison and fined 150,000 RMB (US$21,945). Xinjiang officials on Aug. 6 sentenced Uyghur church leader Alimjan Yimit (Alimujiang Yimiti in Chinese) to 15 years in prison, while a day later, officials in Inner Mongolia sentenced church leaders Li Ming-shun and Zhang Yong-hu to 10 and seven years respectively, with fines of 30,000 (US$4,390) and 20,000 (US$2,925) RMB.
A court in Shanxi Province in November awarded five Linfen church pastors sentences ranging from three to seven years, with fines ranging from 10,000 to 50,000 RMB (US$1,462 to US$7,315). A further five pastors were sentenced to two years in labor camp.
At least 400 paramilitary police violently raided the Fushan county branch of Linfen church on Sept. 13, injuring a few dozen church members, confiscating Bibles and money and damaging church property. A similar raid was carried out on another large church in Shanxi Province in November.
Authorities also sealed or destroyed both house church and TSPM church buildings. In one prominent case last June, officials in Chengdu city, Sichuan Province declared Quiyu church to be an illegal organization, forcing the church to close and confiscating church property.
Officials in Rizhao city, Shandong province, raided a training event at a TSPM church and de-registered two church meeting places, CAA reported, while CHCA reported that officials tore down the meeting place of Changchun church in Ninan city, Shandong Province, giving only token compensation.
Churches in 'Grey' Zone
Chinese scholar and former policy writer Liu Peng believes the government is attempting to remove the "grey" zone in Protestant Christianity, where some churches operate openly without legal status.
China now permits churches to bypass joining the TSPM when registering, but many house church groups reject this solution. Leaders would prefer churches to be in one camp or the other, Liu said in a December interview with the China Daily.
In predicting harsher treatment this year, CAA quoted Wang Zuoan, head of the State Administration for Religious Affairs, who in January told Oriental Outlook that the "reluctance, intimidation and inability" of local governments to deal with religious issues must be addressed.
If these words represent China's religious policy direction in 2010, churches are likely to be targets of greater persecution, CAA concluded.
Report from Compass Direct News

subset: commoncrawl


text:
Nothing about serious illness is easy, but one of the hardest things for parents may be watching their child struggle with pain, stress, and anxiety.
Despite what we may sometimes tell ourselves, stress is not just "in our heads." The stress response — also called the flight-or-fight response — causes a rush of adrenaline and other hormones that trigger physical changes in the body: your heart races, your blood pressure rises, you breathe faster, your digestion slows, and your pupils dilate. Chronic stress takes a toll on the body as well as the mind.
The good news is that using a variety of mind-body relaxation techniques can help short-circuit the flight-or-fight response. Relaxation techniques not only can lessen a child's physical symptoms, they can also help him or her (and you!) regain a sense of control and confidence over a situation, helping everyone find moments of peace amid the chaos and isolation of illness and medical treatment.
These techniques are designed for parents and kids to practice together. Most can be done in a few minutes wherever you are, whether that's a quiet place or a crowded hospital, without any special tools.
However, it's important to note that these techniques should be used as a complement to conventional medical treatment for anxiety and pain, and not as a replacement — doing so could do a child more harm than good.
If your child is suffering from anxiety or pain, ask your doctor what can be done to help. And always check with your health care team to make sure that your child's symptoms are related to stress and not a different medical problem.
Pain and stress can leave a child breathing faster and shallower, or even holding his or her breath — all of which can actually keep the stress response going and heighten the intensity of pain. Paying attention to breathing can help calm the mind.
Try this exercise with your child:
At first, it may be difficult for you and your child to focus on breathing. Distracting thoughts are normal — but rather than following a thought and letting it consume you, try to let it drift out of your mind, like a balloon.
This technique asks a person to focus on breathing and quiet the mind to create a sense of calmness and well-being. And by repeating a word, phrase, or prayer during the exercise, the mind is able to stay focused more easily. When practicing this, it's normal for thoughts to pop into the mind. Tell your child to disregard them and just focus on the word or phrase he or she is repeating.
Resembling an Eastern form of meditation, this technique — called the relaxation response — was popularized and put into Western practice in the 1970s by Herbert Benson, MD. To elicit the relaxation response, follow Steps 1-4, and then:
When practicing, go at your own pace. Don't feel like you have to achieve a deep level of relaxation right away. Often, feelings of calmness and well-being are felt later on or at times of crisis.
To achieve ongoing results, try to practice the technique with your child once or twice daily, but not within 2 hours after eating, as digestion can interfere with the relaxation response. Some people find that the best time to meditate is first thing in the morning, before breakfast.
A growing body of medical research suggests that imagery also can help lessen pain and anxiety, and promote positive feelings. In fact, studies have found that people who practice guided imagery during chemotherapy feel more relaxed and positive about their chemo experience than those who don't use the technique.
Guided imagery (also called "visualization") often works best when a person starts with a few minutes of focused breathing. Here's how it works: With eyes closed, imagine a safe place or a location you once visited that brought a feeling of contentment and joy. Hold on to the image of that place for a while, trying to picture all the sights and sounds:
Getting as descriptive as possible about this safe place will help you and your child get "into" the moment and feel relaxed.
Some children find this exercise more helpful when they are "guided" by a parent, another live instructor, or with a guided imagery CD or DVD.
As with meditation, distracting thoughts will float into the mind as you practice guided imagery. Acknowledge these thoughts, and then let them drift away while you move your attention back to the images in your mind and sounds you hear.
Just as pleasant images can calm the mind and soothe the body, so can music. Kids who undergo music therapy — the research-based use of music to lift moods and promote mental and physical well-being — have been found to have lowered heart rates and blood pressure, and improved anxiety.
Many hospitals provide a licensed, trained music therapist who can work individually with kids to develop a customized treatment plan that engages them in:
To participate in music therapy, your child doesn't need to read music or have any special musical talents. And the best part is that you can practice music therapy at home. By choosing music that both you and your child enjoy — and setting aside time to listen, dance, sing, or experiment with an instrument together — you, too, can teach your child the joys of music.
Energy therapy is based on the understanding that there are electrical currents in all living organisms. This produces magnetic energy fields that extend around and beyond the body, just like the Earth's electromagnetic field. Proponents of this therapy believe that gentle, light touch or above-the-body hand movements can redirect energy to places where it's needed in an effort to bring the body into "balance" or harmony.
Energy therapy continues to be scientifically explored and, and findings note that it promotes healing as it helps kids feel more relaxed, less anxious, and less bothered by pain. It also empowers them to feel like they are in control and can do something to help themselves feel better.
Many different types of energy therapy are practiced all over the world, including Healing Touch, therapeutic touch, Reiki and Johrei (from Japan), and Qi gong (from China).
In the United States, many hospitals offer Healing Touch as a complement to standard treatments for anxiety, pain, or other medical problems, meaning that they are used with the therapies and/or medications that the medical teams order.
And some nurses, doctors, or other health care providers are certified in Healing Touch techniques through a required national certification examination. Healing Touch is the only energy therapy with this requirement. They may be able to offer this service to your child, and can teach you how to practice Healing Touch at home.
If you like to take a more hands-on approach to soothing and comforting your child, you might prefer massage. The benefits of massage are well known, offering muscle relaxation and increased blood flow and oxygen to body parts to help alleviate stress and ease pain.
But some types of massage are not recommended for certain types of conditions, so check with your doctor first before massaging your child or taking your child to a massage therapist.
The most common forms of massage used in complementary medicine include:
Many hospitals have massage therapists on hand to offer massages to both patients and their family members, so find out if massage therapy is offered at your hospital.
These are just a few of the many methods designed to help patients and families cope with pain and anxiety. Many people find that yoga, stretching, or light, gentle exercise also helps to quiet the mind and soothe the body.
To learn more about relaxation techniques, talk to your child's health care team.
Reviewed by: Walle Adams-Gerdts, BA, RN, HTCP/I


text:
Since the 1880s, the automobile and the internal combustion engine have shared a linked fate. The very earliest horseless carriages relied on other methods (obviously) for generating power, but once Karl Benz put a four stroke gasoline engine into a four wheel chassis, the template for the next 130+ years was set.
Henry Ford put his Model T into mass production in 1908 and suddenly the automobile was no longer the preserve of the Edwardian one percent. The adoption of the car by all sectors of society, first in the US and then across the world, has had a profound impact on our way of life. Much of it is overwhelmingly positive, but it hasn't all been good. Our dependence on hydrocarbon fuels in particular may well be our undoing, as atmospheric carbon dioxide levels are skyrocketing, profoundly altering our climate.
As a result, car manufacturers have been looking at alternatives to the traditional way of doing things. We've seen various alternatives appear on the roads in recent years—most commonly hybrid powertrains that couple internal combustion engines with electric motors. But hybrids still emit carbon dioxide from their exhausts, so some argue that purely electric cars are the truly responsible route to 21st century motoring.
Examples of this breed are becoming slightly more common on the road. After General Motors' misstep with the EV-1, Tesla came along and made electric cars sexy with its Lotus-based Roadster. Now companies like Mitsubishi and Nissan offer electric cars for the rest of us.
Mitsubishi's contender is the i-MiEV, an electric car based on the Mitsubishi i (which is a "kei car" sold in the UK, Asia, and other right-hand drive markets that buy Japanese sub-subcompacts). Being nice people, the Mitsubishi folks kindly lent me one for a few days. So what's it like? And could it replace your current commute vehicle?
The aesthetics
The i-MiEV looks unlike almost anything else on the roads. A distinctive "one-box" shape with a wheel at each corner, it's like a mini people carrier. The i-MiEV is a little longer and little wider than the i sold abroad—perhaps to better suit a nation with a bit of a weight problem.
Inside, you sit quite high up, with the car's batteries below the floor. This provides a couple of advantages: the car has a very low center of gravity (CoG) and a it boasts a commanding SUV-like view out over traffic. A particularly nice touch is the window underneath the A pillar, which comes in very handy when parking.
It's not all gravy on the inside, though. The i-MiEV's roots are a cheap and cheerful city car. If it came with a three cylinder petrol engine, you wouldn't expect to pay more than $10,000 for it. Consequently, the fit and fittings really are quite basic. The model we tested was the SE spec, so it came with a hard drive-based navigation system, reversing camera, USB port, and Bluetooth, as well as a leather steering wheel and shift lever. Otherwise the cabin is rather spartan, the plastics are hard and shiny, and the seats are rather basic. You might be paying most of the sticker price for the electric motor and batteries under the floor, but you can buy a Chevy Volt for not much more. (Having spent some time in both, I know where I'd rather idle away my commute.) The cargo space in the rear isn't vast either—slightly more than a Miata, a bit less than Volt.
Still, your hands will spend most of their time with the leather wheel, and that feels good at hand. It has nicely placed controls for the hi-fi and phone, and generally good ergonomics. The dash is centered around a large dial, above and to the left is the battery gauge and transmission display, with the mileage to the right.
In a conventional car, you'd expect the dial to be the rev counter or speedometer. Here, it's separated into three segments: charge, eco, and power. When the needle is in "charge," the i-MiEV is recovering energy through the motor, either because you're braking or coasting (remember, an electric motor in reverse is a generator). When "eco" is showing, you're being most sympathetic to your battery and maximizing range. "Power" should be fairly obvious.
About that powertrain: the i-MiEV has a 66 bhp motor driving the rear wheels. It doesn't sound high—especially considering that it weighs around 3,300 lbs in SE trim—but, like a diesel, the more important figure is the torque output. Torque is pretty good at 145 lb-ft, and almost all of that is available straight away. Electric motors, unlike internal combustion engines, make almost all of their torque even at very low revs.
The shifter has the look of a conventional automatic but, this being an electric car, there's no need for gears as such. Instead, there are three different modes of forward propulsion. Drive is the most straightforward and delivers the most power. Eco softens throttle response and increases energy regeneration, and Braking maximizes energy recovery. As such, D is for going up hills, merging onto freeways, and general hooning. Eco is for everyday driving; B is best left for going downhill.
The driving experience
Turn the key and the dash lights up, coupled with an audio chime; you're ready to go. It's a little disconcerting not to hear any sort of noise from an engine, something that the occasional surprised pedestrian would probably agree with.
Even in Eco, the i-MiEV is relatively peppy off the line, with good traction from the rear wheels. Handling isn't bad, courtesy of that low CoG, but the special low rolling resistance tires don't have a huge amount of grip. You'll want to take those sweeping on-ramps with a degree of respect for them, rather than flat out.
Then again, driving the i-MiEV flat out sort of defeats the point. It's based on a city car, and it's at home driving around town, not carving canyons or clipping cones at an autocross. And of course, the harder you drive, the shorter your range.
No, with the i-MiEV it makes more sense to leave it in Eco and to drive around sedately, keeping the needle pegged in the Eco zone. In this regard it's quite similar to the Volt, which also encourages the driver to put economy ahead of speed by gamifying the driving experience. Despite being a bit of a speed demon normally, I found myself feeling quite guilty when the needle edged into the "power" band. The driving position was a bit of a hindrance in this regard, as I found it hard to keep an eye on the road and see the dial in my peripherals at the same time. Taller drivers probably wouldn't have that issue, though.


text:
Wedding planning tips for grooms
When it comes to planning a wedding, some grooms may feel left out of the planning as the bride tends to most of the details. But a wedding day is also an important day for the groom and it's important the day reflects his interests as well.
One way the groom can make sure he's more involved in the wedding process is to think of at least one detail he really wants to take care of himself. This can be something small, like a food item that will be served, or it can be something larger like choosing a photographer or the band. If a particular element of the wedding is really important to him than he should make sure he gets to take point on the planning of it.
Another way for the groom to stay involved is to attend appointments with various people the couple has hired to assist with the wedding, from the wedding planner, to the chef, to the staff at the venue. Being present will allow the groom to help with decisions that are made during these meetings.
And perhaps the most important role a groom can play in the wedding preparation is to keep the bride calm. Planning a wedding can be stressful so the bride and groom need to support each other throughout the process.


text:
Microwave Oven Service Center in Hyderabad Telangana
Are you hunting for Microwave Oven Service Center in Hyderabad Telangana, Service4help is your best choice for home appliances service and repair. We manage a wide range of brands overhauling furthermore offer of extra parts and embellishments of home apparatus items. Our expert specialists are experienced. Our experts are all around prepared and high informative. Our adage is to give best answers for our clients with moderate charges. We have practical experience in service and repair, at your doorstep. For Washing Machine Service booking fill our online enquiry structure. Our administration specialist will call you. We will give same day service.


text:
Listed PSOs
Below is a list of PSOs that are currently listed by AHRQ. A healthcare provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.
Use the categories on the left to filter the list of PSOs or search a PSO name. There are 5 total PSOs listed by AHRQ.
Results1 - 5 of 5 Listed PSOs
Alternate Legal Name: Missouri Center for Patient Safety
Phone Number: (573) 636-1014
State: Missouri
Phone Number: (866) 247-3004
State: Pennsylvania
Components of Parent Organizations:
- Emergency Care Research Institute d/b/a ECRI
Alternate Legal Name: Mission PSO, Inc.
Phone Number: (999) 999-9999
State: Pennsylvania
Phone Number: (804) 965-1226
State: Virginia
Components of Parent Organizations:
- Virginia Hospital and Healthcare Association
- Virginia Hospital Research and Education Foundation
Phone Number: (312) 775-4100
State: Illinois
Components of Parent Organizations:
- Vizient Inc


text: Collegiate Flags > Hawaii Rainbows Flag March Madness Logo Pennant View All Hawaii Rainbows Flag ITEMS Quantity $10.95 Out of Stock Add to Cart IN STOCK Standard and Express Shipping Standard: 3-7 Days | Express: 1-3 Days Buy Now Item ID#: WN-43136819 Tweet Wish Our March Madness Logo Pennant is perfect for showing your College Basketball March Madness allegiance in any room of the house. The March Madness Logo Pennant is full size (12x30 inches) and is single-sided screen printed with the officially licensed logo or insignia as shown. Our pennants are made of felt and provide a pennant sleeve for insertion of a pennant stick, if desired.Accessorize your pennant with our Pennant Sticks, Pennant Frames, or buy one of your favorite College Pennant Sets. Genuine Merchandise and Officially Licensed by WinCraft, Inc. Featured Items American USA 3x5 Polyester Flag$7.95 American USA House Banner$12.95 USA American Yard Garden Banner$0.95 USA Nautical Boat Golf Cart Flag$9.95 USA Flag Mini Garden Flag and Table Topper$10.95 Please Slow Down Sign Garden Flag and Holder$28.95 Related Items Pennant for the Big 10 Conference$9.95 NCAA College Football Playoff Pennant$9.95 College Flags and Banners Co Branded Logo Flag$29.95 Big Ten Conference 2x3 Flag$22.95 Customers Also Bought Flag & Pennant Accessories Pennant Sticks $6.95 Out of Stock Add To Cart Wood Pennant Frame for 12"x30" Pennants $47.95 Out of Stock Add To Cart


text:
Directory of Services
xx Page generated: May 31, 2023, 1:47:27 AM", "Today is May 31, 2023", "The current time is 1:47:27 AM 2023-05-31 01:47:27 AM
Search results
Fully-matching results
Postnatal Weight Loss and Weight Loss for Mums
I support Mums to lose weight and feel good about themselves. I also specialise in postnatal and child weight loss. I help Mums take the pressure off themselves, so life feels a little bit lighter. provide Mums with the support they need to lose


text:
Once again, the folks from Fallen Fruit are descending upon the museum for a special EATLACMA event this Sunday: the Public Fruit Jam.
Bring your homegrown or street-picked fruit and join in to make collective fruit jams! By the end of the event we hope you'll have made some new friends as well some wild new jam. The event is free, but space is limited, given on a first-come first-served basis.
While you're here, be sure to check out the EATLACMA exhibition as well as the shows for John Baldessari, Thomas Eakins, and Catherine Opie.
This weekend also marks the final screenings for our Ernst Lubitsch series. Friday night sees two early silent films, The Marriage Circle (1924) and So This is Paris (1926), both featuring live musical accompaniment by Robert Israel. On Saturday, for our final two screenings, we've got Lubitsch's only color film, Heaven Can Wait (1943), starring Don Ameche, and Lubitsch's last film, Cluny Brown (1946).
Lots of great concerts this weekend too—perfect for date night, whichever night you so choose. Tonight jazz vocalist Sara Gazarek will perform in the BP Grand Entrance starting at 6 pm. (Get here early and you can also check out the galleries—they're free after 5 pm for L.A. County residents.) Saturday evening Bill Cunliffe leads Imaginacion as they perform Latin jazz in Hancock Park, also free. And, on Sunday, the Helios Guitar Quartet will take to the Bing Theater to perform selections from Bach's Well-Tempered Clavier and other works.
Want samples? Videos for Gazarek and the Helios Guitar Quartet are below; you can hear samples of Cunliffe and Imaginacion at their MySpace site.


text:
One of the best things about being a resto druid – other than tree form, awesome hots, and the general coolness of it all – is the rest of the blogosphere of resto druids. Seriously some of the best, most talented bloggers out there are resto druids.
For instance, are you wondering about gear for getting ready to raid in Cataclysm? Lissana can help you out. So can Naora and Maedred and Angelya
Resto druiding in Cataclysm in general? Start with Lissana (Currently aimed at level 80s in 4.0.3a, she'll update to 85 shortly) or her Cata Leveling Guide if you want to level in your offspec (because tree punches don't always cut it). Keeva's Guide will be around soon and will be well worth the wait, believe me. Bookmark it now if you haven't.
What professions you should think about? Keeva's got you covered.
Healing in general? Lissana's always a good place to start. A very insightful post from Cannot Be Tamed compares heals across all 5 Healing specs – highly recommended reading, just to really understand your partners in heals, if nothing else. And, to toot my own horn, my old posts on Triage and staying calm are more relevant now than when I first wrote them. And Reversion post about understanding the "shape" of a fight's damage, while designed for tanks, has a lot that healers should know, too.
So, yeah. All those links are written by people with resto druid main or off specs. What can I say? Clearly the true spec for bloggers must be Tree.
After all, we all communicate electronically, saving lots of paper, and hence, trees.
Save the Trees!


text:
British multinational bank HSBC has launched a new US$ 100 million, five year partnership with WaterAid, WWF and the Earthwatch Institute. The HSBC Water Programme will bring safe water and improved sanitation to over a million people; tackle water risks in river basins; and raise awareness about the global water challenge.
The programme is backed-up by report [1] commissioned by HSBC, which warns that the predicted high-growth rate in several of the world's most populous river basins may not materialise because of their unsustainable water consumption . The report also highlights "the powerful economic rationale for improving access to freshwater and sanitation, at a time when total aid for water access and sanitation has actually declined".
Providing universal access to safe water and sanitation would imply potential economic gain of US$ 220 billion per year, the report said. It stated that the average return on each dollar invested in universal access was just under US$ 5, even after taking maintenance costs into account. In Latin America the figure is US$ 16 while in some African countries, the capital investment would be paid back in only three years. Several countries in Africa and Latin America would gain an average of more than 15% of their annual GDP from achieving universal access.
As part of the HSBC Water Programme, WaterAid will provide clean water to 1.1 million people and sanitation and hygiene education to 1.9 million people in Bangladesh, India, Nepal, Pakistan, Nigeria and Ghana. Priorities include educating adolescent girls on menstrual hygiene management; providing separate water and sanitation facilities in schools; and influencing national and local governments to prioritise water and sanitation services.
WWF will work with local authorities, businesses and communities to implement new practices and policies for five key basins: the Yangtze, Ganges, Mekong, Pantanal and Rift Valley. Earthwatch will be engaging over 100,000 HSBC employees in monitoring and research of freshwater resources worldwide.
View the HSBC Water Programme video from WaterAid.
The HSBC Water Programme is a follow-up to the US$ 100 million HSBC Climate Partnership (2007-2011), which also included WWF and Earthwatch are partners.
[1] Frontier Economics, 2012. Exploring the links between water and economic growth : a report prepared for HSBC. London, UK;: Frontier Economics. Available at: <http://www.thewaterhub.org/research/>
Related news:
- Developing countries and donors agree to tackle the water and sanitation crisis, E-Source, 30 May 2012
- Prioritise slum dwellers for water and sanitation investment, says WaterAid manifesto, E-Source, 28 Oct 2011
Related web site: HSBC Water Programme – www.thewaterhub.org
Source: HSBC, 11 Jun 2012 ; Damian Carrington, Rivers will generate a quarter of GDP by 2050, study shows, Guardian, 11 Jun 2012


text:
Monday night Rev and I log onto Argent Dawn to see what SAN is up to. There's a few folk around, so we decide to re-attempt Blackwing Lair. Hairy and Daruma join, as do Missholloway, Rogerstring, our soulstone-slave Invariant (my RAF alt, on follow and not doing anything) and Norinka, a SAN druid who hadn't joined us before.
First, we got attuned. We found the guy who drops the letter that starts the quest (that Jack built? wait…) outside of Blackrock Spire, cleared UBRS fast, and touched the orb behind the dragon boss there. Then we could use the orb outside the instance to get in BWL.
First boss was still dead from our weekend attempt so we went and faced down the corrupted red dragon, the one that dots you with a dot that kills you at the end. We had it carefully planned; Consolidate was Soulstoned and would Brez me, Norinka would Brez if she could, and we'd just burn him down.
We started. Daruma threw Heroism, I popped my wings, tanked, got dotted, died, got rezzed, re-taunted – and he dropped before too many more of us did.
Hilariously, Hairygiblets and Rogerstring still had the dot at the end. Five seconds later as we're examining loot, they drop dead…
We continue upstairs and find a room full of pillars, whelps, and a slowing field. None of us knew what to do; a guildie who wasn't there mentioned that a stealthed rogue could disable the field. Great! Except… we didn't have a rogue. Oh well. We started wading through the room in slow motion, me trying to grab aggro, wishing paladins had a charge… Hand of Freedom wasn't really helping (it didn't remove the slow effect but would prevent one re-application sometimes)
Invariant, being low level, died from aoe or something. So did Rogerstring. I decided we should press on to the end, hope that killing the boss at the end would stop the field and let us get out of combat (the whelps just kept respawning) so we could rez. This is important.
The supressor whelp room is actually two floors. Invariant was dead on the first floor. The rest of us pressed slowly onward, like something from a bad horror movie. The kind with endlessly spawning whelps.
We found a boss, killed him. The field didn't drop, but the room just past didn't have it. I decided to start clearing trash while Consolidate slowly made his way down to get Invariant. At this point Consolidate was the only one healing. This is important too.
I pulled a few trash mobs, planning to kill them before they could kill me. It was working – until out of nowhere there's a DRAGON in my FACE eating my SPLEEN. Through my face. Yeah. And he knocked me back into 9000 adds, who instantly start whacking me. I tried healing myself but kept getting interrupted. Most of us died right then. I sighed.
Consolidate was downstairs, and not dead, and I'm thinking he can rez me when I hear a "whoa!" behind me and turn to look at his screen. The dragon had just summoned him! We hadn't known it would do that.
Long story short – we all ran back.
We again started clearing trash in the room and again the dragon appears, but this time we're ready and take him down! Not that bad as long as there's heals in the room.
More trash dies. Some of it was nasty, with lots of shadow bolts. Some of it resisted magical damage, ie Holy damage, ie there I was futilely throwing my abilities around and keeping aggro mostly by force of will. Fortunately we had a hunter, and when Norinka shifted to cat, things really died.
We moved into a big room – the whole place was very cool, lots of draconic experimental remains lying around – and see a dragon, some big dudes, and a dragon in the room that followed. Wise to their tricks, we killed the trash behind us, then pulled the dragon. Sure enough he knocked us around like crazy, but we prevailed!
By this time it was late, so we called it for the night, agreed to extend our lockout and finish up Tuesday.
Tuesday rolls around and so does patch 3.3.5. And the servers are DOWN! Sigh. Reversion and I are forced to spend quality time together, play with our daughter, go for ice cream… then, just at Nomster's bedtime, the servers were up. Sort of. Once we got through, there was a number of SAN folk around so we re-grouped up, asked if anyone else wanted to finish the place, and started summoning.
Well, other people did want to come. They kept coming as we progressed, so here's the final list:
Divergent – me – paladin
Consolidate – Reversion – druid
Hairygiblets – hunter
Daruma – shaman
Tasteless – druid
Shiftless- druid
Norinka – druid
Dropout – paladin
Edamaxim – dk
Enyss – druid
Vet – hunter
Missholloway – paladin
Rogerstring – shaman
Invariant – useless
(no order here, this is how they appeared in one screenshot I have)
So some subset of us kill that dragon we'd left alive the night before, then Chromagnus the penultimate boss, a two headed dragon-corehoundy-looking-thing. And there we were, on Nefarion's balcony.
He didn't look that impressive sitting on the throne, even if his head was on fire, but he was a real raid boss. Vet had lot of experience killing him and gave us a rundown – kill adds coming through the doors on phase one, take him by the balcony on phase 2, beware of "class calls" – incidentally, I was really impressed that they added a class call for DKs. That's a nice touch. Most of us seriously overgeared the place and the class calls ended up not being an issue for anyone but the hunters who had to un-equip their bows or they'd get broken.
So we fought him. During part of it, Invariant died, and Nefarion called out the line I have as the title for the post, heh.
And then – he died.
SAN is hoping to go to Molten Core tonight. After that… who knows but we're loving the old school raids as we wait to get enough 80s to do Ulduar and ICC. If you're on an American server and this sounds fun, join us! Roll an alt or transfer and come play!


text: Published February 27, 2018 at 3264 × 2448 in Farming Land Before-During and Today ‹ Return to post Leave a Reply Cancel reply Enter your comment here... Fill in your details below or click an icon to log in: Email (required) (Address never made public) Name (required) Website You are commenting using your WordPress.com account. ( Log Out / Change ) You are commenting using your Facebook account. ( Log Out / Change ) Cancel Connecting to %s Notify me of new comments via email. Notify me of new posts via email. Δ This site uses Akismet to reduce spam. Learn how your comment data is processed.


text:
Samsung Seeks Broader Chip Base as Apple Cuts Loose
Samsung Electronics Co is looking to supply chips to more Chinese and other emerging smartphone makers, the head of its system chip business said, to counter any fall-off in demand from Apple Inc (NASDAQ:AAPL), which is weaning itself off Samsung chips used in its iPhones and iPads.
Samsung and its main U.S. rival, and biggest customer, together account for more than half the global smartphone market, and the South Korean group is the main supplier of mobile processors, or application processors (AP), powering both Apple devices and its own range of Galaxy phones and tablets.
But, as Apple looks to be less reliant on its rival for parts for its gadgets - it is already buying fewer Samsung memory chips and display screens as the two have gone to war over patents - concerns have grown that Samsung may see its processor revenues tumble.
"As there are just two smartphone makers that are doing really well, chipmakers supplying them have grown in tandem. So we plan to bolster our relationship with those key customers," Stephen Woo, president of Samsung's System LSI business, which makes processors for Apple products, said in an interview.
Supplying processors for Apple products has been the mainstay of Samsung's system chips business.
Goldman Sachs (NYSE:GS) estimates Samsung's AP chip sales to Apple will rise to 9.3 trillion won ($8.8 billion) this year, or nearly 80 percent of Apple's spending on Samsung processing chips, memory chips and flat screens. But that could tumble to just 2.5 trillion won next year, as Apple will shift 30 percent of its AP business from Samsung and eventually 80 percent by 2017, according to Goldman.
"(We) should diversify our customer base and are making such efforts already, adding some Chinese customers," Woo told Reuters ahead of his first keynote speech at the annual Consumer Electronics Show in Las Vegas on Wednesday.
China's Meizu, one of the local smartphone newcomers, uses Samsung's Exynos quad-core chip for its MX smartphone, and Lenovo's K860 LePhone is also powered by Exynos.
Still, Samsung's mobile processor business is almost entirely tied to the fortunes of Apple and its own mobile business - the Galaxy range. By comparison, chip rivals such as Qualcomm Inc (NASDAQ:QCOM), Texas Instruments and Nvidia have a broader client base - from LG Electronics Inc and Nokia to HTC Corp, Huawei Technologies Co and Google's Motorola (NASDAQ:GOOG).
"We see emerging players who have potential to grow in smartphones and we will continue to make efforts to supply them with our chips," Woo said.
The mobile processor market, driven by roaring sales of smartphones and tablets, is a bright spot for a semiconductor industry that is struggling with falling computer sales. Research firm Gartner estimates the mobile processor market will grow 30 percent this year to $13.5 billion and hit $16.5 billion next year.
To strengthen its chip capability, Samsung bought UK chipmaker CSR Plc's mobile phone connectivity and location technology for $310 million last year, and it is now looking at how it can improve modem chip technology, especially the baseband chip solution that enables wireless devices' radio communications.
"Baseband is a very important segment, but we don't have it. Given its importance, we're reviewing various options," Woo said, suggesting Samsung could be scouting for potential targets.
Qualcomm is the biggest baseband chip company with nearly 50 percent of the market, followed by the likes of Mediatek, Texas Instruments and Broadcom.
Chipmakers are increasingly seeking to produce a single chip solution that combines AP, modem chip and connectivity chips that support Wi-Fi, Bluetooth and near-field communication functions, in one chipset. This combo-package is popular among low-end smartphones as it allows phone makers to cram various chips into compact devices.
Woo said Samsung, however, was not considering expanding into a single chip solution and will instead continue to focus on pure AP chips favored for high-end phones, as it allows manufacturers to differentiate their hardware offerings with various chip combinations.
The explosion of mobile devices has opened a big opportunity to Samsung as Intel Corp, the world's top chipmaker, struggles to crack the mobile processor market dominated by the makers of ARM Holdings licensed chips. Samsung is the biggest maker of ARM-based chips, such as Apple chips and Samsung's Exynos brand.
Intel's market share in mobile devices is just 1 percent, as UK chip designer ARM holds a near monopoly.
Woo said Samsung was not looking to break into the desktop computer or server processor market - which Intel dominates, but is under threat from ARM-based chips that boast low-power consumption and compact design.
"For the time being, our focus will pretty much be on enhancing our AP offering, especially for high-end mobile devices," he said.
($1 = 1062.9500 Korean won)
(Editing by Ian Geoghegan)


text:
List of Faculty Publications
Below is a list of Faculty publications imported from PubMed or manually added. By default, publications are sorted by year with titles displayed in ascending alphabetical order.
Shortcuts: Wühr, Martin | Wingreen, Ned | Wieschaus, Eric | Troyanskaya, Olga | Tilghman, Shirley | Storey, John | Singh, Mona | Shvartsman, Stanislav | Shaevitz, Joshua | Rabinowitz, Joshua | Murphy, Coleen | Levine, Michael {Levine, Michael S.} | Gregor, Thomas | Botstein, David | Bialek, William | Ayroles, Julien | Andolfatto, Peter | Akey, Joshua
"RNA surveillance via nonsense-mediated mRNA decay is crucial for longevity in daf-2/insulin/IGF-1 mutant C. elegans.", Nat Commun, vol. 8, p. 14749, 2017.,


text:
of video's waiting for you inside
Brunette friends Tia and Jo rub each other in sun-cream.
You must be logged in to post a comment.
This site uses functional cookies and external scripts to improve your experience.
This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.
You can find more information on our %privacy_policy% page.
NOTE: These settings will only apply to the browser and device you are currently using.
Analytical cookies help us improve our website by collecting and reporting information on its usage.
These are cookies that are required for the operation of our websites. They include, for example, cookies that enable you to log into secure areas.


text:
Results found: 0
We use cookies to give you a great and free experience. By continuing to browse the site you are agreeing to our use of cookies.
You can change your Cookie settings at any time. (Essential cookies are for: preferences, security, performance analytics and contextual advertising)Privacy policy » Continue


text:
A London design consultancy has developed a cheap, clean, and safer alternative to the kerosene lamp. Kerosene burning lamps are thought to be used by over a billion people in developing nations, often in remote rural parts where electricity is either prohibitively expensive or simply unavailable. Kerosene's potential replacement, GravityLight, is powered by gravity without the need of a battery—it's also seen by its creators as a superior alternative to solar-powered lamps.
Kerosene lamps are problematic in three ways: they release pollutants which can contribute to respiratory disease; they pose a fire risk; and, thanks to the ongoing need to buy kerosene fuel, they are expensive to run. Research out of Brown University from July of last year called kerosene lamps a "significant contributor to respiratory diseases, which kill over 1.5 million people every year" in developing countries. The same paper found that kerosene lamps were responsible for 70 percent of fires (which cause 300,000 deaths every year) and 80 percent of burns. The World Bank has compared the indoor use of a kerosene lamp with smoking two packs of cigarettes per day.
The economics of the kerosene lamps are nearly as problematic, with the fuel costing many rural families a significant proportion of their money. The designers of the GravityLight say 10 to 20 percent of household income is typical, and they describe kerosene as a poverty trap, locking people into a "permanent state of subsistence living." Considering that the median rural price of kerosene in Tanzania, Mali, Ghana, Kenya, and Senegal is $1.30 per liter, and the average rural income in Tanzania is under $9 per month, the designers' figures seem depressingly plausible.
Approached by the charity Solar Aid to design a solar-powered LED alternative, London design consultancy Therefore shifted the emphasis away from solar, which requires expensive batteries that degrade over time. The company's answer is both more simple and more radical: an LED lamp driven by a bag of sand, earth, or stones, pulled toward the Earth by gravity.
It takes only seconds to hoist the bag into place, after which the lamp provides up to half an hour of ambient light, or about 18 minutes of brighter task lighting. Though it isn't clear quite how much light the GravityLight emits, its makers insist it is more than a kerosene lamp. Also unclear are the precise inner workings of the device, though clearly the weighted bag pulls a cord, driving an inner mechanism with a low-powered dynamo, with the aid of some robust plastic gearing. Talking to Ars by telephone, Therefore's Jim Fullalove was loath to divulge details, but did reveal the gearing took the kinetic energy from a weighted bag descending at a rate of a millimeter per second to power a dynamo spinning at 2000rpm.
The company has turned to indiegogo to crowdfund an initial run of 1,000 GravityLights. These will be given to rural villagers in India, and in several African countries for testing, with their feedback informing the design of an improved Mark II version for wider manufacture. Though GravityLights are expected to cost $10, it's hoped that the refined, more efficient Mark II GravityLight will cost $5 or less. Its makers assert that for villages in the developing world, a $10 GravityLight would pay for itself within three months by negating the need to buy kerosene.
Ultimately, GravityLight's creators envision a time when the device could become a low-powered off-grid energy hub for remote homes, powering not only a light (or a string of lights) but perhaps also phones or e-reader Wikipedia clients that connect, with or without cables, to the GravityLight. These are all long-term projects that form the company's deciwatt research initiative, though such projects may be dependent upon cell tower or satellite availability. Their goal for now, though, is to establish the GravityLight itself.
At the time of writing, the funding campaign has received over $380,000—well in excess of the $55,000 goal and enabling the development of accessories. Among the available pledges, $25 will sponsor a GravityLight for shipping to the developing world, while $60 will do the same—and secure a GravityLight of your own.


text:
Baseball is in the air, and the WeLoveDC blog and the Nationals are kicking off the season by sponsoring a special event for fans of the Nats, the racing presidents, and of course, Teddy Roosevelt.
On Wednesday, April 21, with the Rockies in town for the Nats' first extended homestand, we'll be going behind the scenes for a private tour and pre-game rally, plus prizes, sign-making, and an opportunity to go down on the field before the game.
WeLoveDC has packaged all this into a $40 ticket, which also includes entrance to the game, a $10 food voucher, and a seat amid the Teddy Roosevelt cheering section in section 237 by the scoreboard bar.
5:30 p.m. Tour of the stadium. We'll go behind the scenes, tour the press box, and four lucky raffle winners will get to go down to field level.
6:00 p.m. Pre-game rally, with sign-making materials, prizes, and Nats trivia.
7:05 p.m. First pitch
Tickets went on sale today at eventbrite and will sell out, so order yours now.


text:
Posted in:
by Dave Graveline
January 13, 2023
Comments are off
by Dave Graveline
September 29, 2022
Comments are off
by Dave Graveline
June 2, 2023
Comments are off
You are here:
ShareFacebook, Twitter, Google Plus, Pinterest, Email
Dave Graveline
January 18, 2019, 8:05 pm
Comments are off
Podcast: Play in new window | Embed
Dave talks to Andy Mallinger, Senior Director of Consumer Products at Webroot
Tagged with: CES 2019 Part 2 Hour 3
Dave Graveline is the founder, Host & Executive Producer of "Into Tomorrow" in addition to being President of the Advanced Media Network".
Dave is also a trusted and familiar voice on many national commercials & narrations in addition to being an authority in consumer tech since 1994. He is also a former Police Officer and an FBI Certified Instructor.
Dave thrives on audience participation!
See more


text:
We've all experienced love. We've loved (and been loved by) parents, brothers, sisters, friends, even pets. But romantic love is different. It's an intense, new feeling unlike any of these other ways of loving.
Why Do We Fall in Love?
Loving and being loved adds richness to our lives. When people feel close to others they are happier and even healthier. Love helps us feel important, understood, and secure.
But each kind of love has its own distinctive feel. The kind of love we feel for a parent is different from our love for a baby brother or best friend. And the kind of love we feel in romantic relationships is its own unique type of love.
Our ability to feel romantic love develops during adolescence. Teens all over the world notice passionate feelings of attraction. Even in cultures where people are not allowed to act on or express these feelings, they're still there. It's a natural part of growing up to develop romantic feelings and sexual attractions to others. These new feelings can be exciting — or even confusing at first.
The Magical Ingredients of Love Relationships
Love is such a powerful human emotion that experts are constantly studying it. They've discovered that love has three main qualities:
- Attraction is the "chemistry" part of love. It's all about the physical — even sexual — interest that two people have in each other. Attraction is responsible for the desire we feel to kiss and hold the object of our affection. Attraction is also what's behind the flushed, nervous-but-excited way we feel when that person is near.
- Closeness is the bond that develops when we share thoughts and feelings that we don't share with anyone else. When you have this feeling of closeness with your boyfriend or girlfriend, you feel supported, cared for, understood, and accepted for who you are. Trust is a big part of this.
- Commitment is the promise or decision to stick by the other person through the ups and downs of the relationship.
These three qualities of love can be combined in different ways to make different kinds of relationships. For example, closeness without attraction is the kind of love we feel for best friends. We share secrets and personal stuff with them, we support them, and they stand by us. But we are not romantically interested in them.
Attraction without closeness is more like a crush or infatuation. You're attracted to someone physically but don't know the person well enough yet to feel the closeness that comes from sharing personal experiences and feelings.
Romantic love is when attraction and closeness are combined. Lots of relationships grow out of an initial attraction (a crush or "love at first sight") and develop into closeness. It's also possible for a friendship to move from closeness into attraction as two people realize their relationship is more than "just like" and they have become interested in one another in a romantic way.
For people falling in love for the first time, it can be hard to tell the difference between the intense, new feelings of physical attraction and the deeper closeness that goes with being in love.
Lasting Love or Fun Fling?
The third ingredient in a love relationship, commitment, is about wanting and deciding to stay together as a couple in the future — despite any changes and challenges that life brings.
Sometimes couples who fall in love in high school develop committed relationships that last. Many relationships don't last, though. But it's not because teens aren't capable of deep loving.
We typically have shorter relationships as teens because adolescence is a time when we instinctively seek lots of different experiences and try out different things. It's all part of discovering who we are, what we value, and what we want out of life.
Another reason we tend to have shorter relationships in our teens is because the things we want to get out of a romantic relationship change as we get a little older. In our teens — especially for guys — relationships are mainly about physical attraction. But by the time guys reach 20 or so, they rate a person's inner qualities as most important. Teen girls emphasize closeness as most important — although they don't mind if a potential love interest is cute too!
In our teens, relationships are mostly about having fun. Dating can seem like a great way to have someone to go places with and do things with. Dating can also be a way to fit in. If our friends are all dating someone, we might put pressure on ourselves to find a boyfriend or girlfriend too.
For some people dating is even a status thing. It can almost seem like another version of cliques: The pressure to go out with the "right" person in the "right" group can make dating a lot less fun than it should be — and not so much about love!
In our late teens, though, relationships are less about going out to have fun and fitting in. Closeness, sharing, and confiding become more important to both guys and girls. By the time they reach their twenties, most girls and guys value support, closeness, and communication, as well as passion. This is the time when people start thinking about finding someone they can commit to in the long run — a love that will last.
What Makes a Good Relationship?
When people first experience falling in love, it often starts as attraction. Sexual feelings can also be a part of this attraction. People at this stage might daydream about a crush or a new BF or GF. They may doodle the person's name or think of their special someone while a particular song is playing.
It sure feels like love. But it's not love yet. It hasn't had time to grow into emotional closeness that's needed for love. Because feelings of attraction and sexual interest are new, and they're directed at a person we want a relationship with, it's not surprising we confuse attraction with love. It's all so intense, exciting, and hard to sort out.
The crazy intensity of the passion and attraction phase fades a bit after a while. Like putting all our energy into winning a race, this kind of passion is exhilarating but far too extreme to keep going forever. If a relationship is destined to last, this is where closeness enters the picture. The early passionate intensity may fade, but a deep affectionate attachment takes its place.
Some of the ways people grow close are:
- Learning to give and receive. A healthy relationship is about both people, not how much one person can get from (or give to) the other.
- Revealing feelings. A supportive, caring relationship allows people to reveal details about themselves — their likes and dislikes, dreams and worries, proud moments, disappointments, fears, and weaknesses.
- Listening and supporting. When two people care, they offer support when the other person is feeling vulnerable or afraid. They don't put down or insult their partner, even when they disagree.
Giving, receiving, revealing, and supporting is a back-and-forth process: One person shares a detail, then the other person shares something, then the first person feels safe enough to share a little more. In this way, the relationship gradually builds into a place of openness, trust, and support where each partner knows that the other will be there when times are tough. Both feel liked and accepted for who they are.
The passion and attraction the couple felt early on in the relationship isn't lost. It's just different. In healthy, long-term relationships, couples often find that intense passion comes and goes at different times. But the closeness is always there.
Sometimes, though, a couple loses the closeness. For adults, relationships can sometimes turn into what experts call "empty love." This means that the closeness and attraction they once felt is gone, and they stay together only out of commitment. This is not usually a problem for teens, but there are other reasons why relationships end.
Why Do Relationships End?
Love is delicate. It needs to be cared for and nurtured if it is to last through time. Just like friendships, relationships can fail if they are not given enough time and attention. This is one reason why some couples might not last — perhaps someone is so busy with school, extracurriculars, and work that he or she has less time for a relationship. Or maybe a relationship ends when people graduate and go to separate colleges or take different career paths.
For some teens, a couple may grow apart because the things that are important to them change as they mature. Or maybe each person wants different things out of the relationship. Sometimes both people realize the relationship has reached its end; sometimes one person feels this way when the other does not.
Moving On
Losing love can be painful for anyone. But if it's your first real love and the relationship ends before you want it to, feelings of loss can seem overwhelming. Like the feelings of passion early in the relationship, the newness and rawness of grief and loss can be intense — and devastating. There's a reason why they call it a broken heart.
When a relationship ends, people really need support. Losing a first love isn't something we've been emotionally prepared to cope with. It can help to have close friends and family members to lean on. Unfortunately, lots of people — often adults — expect younger people to bounce back and "just get over it." If your heart is broken, find someone you can talk to who really understands the pain you're going through.
It seems hard to believe when you're brokenhearted that you can ever feel better. But gradually these feelings grow less intense. Eventually, people move on to other relationships and experiences.
Relationships — whether they last 2 weeks, 2 months, 2 years, or a lifetime — are all opportunities to experience love on its many different levels. We learn both how to love and how to be loved in return.
Romance provides us with a chance to discover our own selves as we share with someone new. We learn the things we love about ourselves, the things we'd like to change, and the qualities and values we look for in a partner.
Loving relationships teach us self-respect as well as respect for others. Love is one of the most fulfilling things we can have in our lives. If romance hasn't found you yet, don't worry — there's plenty of time. And the right person is worth the wait.


text:
Sorry, we do not currently have any featured inventory on our website.
Please call 540-382-2100 for further assistance.
* MSRP is the Manufacturer's Suggested Retail Price (MSRP) of the vehicle. Unless specifically indicated in the advertisement, MSRP does not include taxes, fees or other charges. Actual dealer pricing may vary. Consult your dealer for more information and complete details.
* The dealer advertised price may not reflect specific dealer offers, and may be subject to certain terms and conditions as indicated in the advertisement. Consult your dealer for more information and complete details.
* Images and options shown are examples, only, and may not reflect exact vehicle color, trim, options, pricing or other specifications.


text:
Dow surges a second day, closes in on record
The Dow came within 100 points of its all-time high Wednesday after rising sharply for a second straight day.
The market surged following more evidence that the Fed will keep interest rates low, housing will keep recovering and shoppers aren't pulling back on spending, even with a payroll tax hike.
The gains were broad: Twenty-nine of 30 stocks in the Dow Jones industrial average rose. All 10 industries in the Standard and Poor's 500 index climbed.
The Dow Jones industrial average rose 175.24 points, or 1.2 percent, to 14,075.37. The index is now less than 100 points away from its record close of 14,164 reached in October 2007.
The Dow has surged 290 points in the past two days, erasing its drop of 216 points Monday when inconclusive results from an election in Italy renewed worries that Europe's fiscal crisis could flare up again.
"The market psychology has clearly shifted. It's no longer sell the rally, it's buy the dips," said Dan Veru, chief investment officer of Palisade Capital Management. "The economic data continues to be strong."
Stocks have surged since the start of the year. The Dow is up 7.4 percent.
Earnings for S&P 500 companies will climb 7.8 percent in the fourth quarter, the third straight quarter of growth, according to data from S&P Capital IQ.
The Standard and Poor's 500 index gained 19.05 points, or 1.3 percent, to 1,515.99. The Nasdaq composite rose 32.61 points, or 1.3 percent, to 3,162.26. The index is 6.5 percent higher for the year, and is about 3.1 percent short of its record close of 1,565.
Investors were also encouraged Wednesday that Federal Reserve Chairman Ben Bernanke stood behind the central bank's low-interest-rate policies as he faced lawmakers for a second day. His comments dissipated worries about the bank's resolve to keep up the program. Those worries sprung up last week when minutes from the bank's last policy meeting revealed disagreement among Fed officials.
Also, the number of Americans who signed contracts to buy homes rose in January from December to the highest level in almost three years. The report continued a string of positive housing news. Sales of new homes jumped 16 percent last month to the highest level since July 2008, the government reported Tuesday.
Home builder stocks rose for the second day in a row. PulteGroup climbed 25 cents, or 1.3 percent, to $19.30, after rising 5.7 percent the day before. The government reported Tuesday that sales of new homes jumped 16 percent last month.
"Some encouraging news for the bulls has been the housing data that has come out over the past couple of days," said Todd Salamone, director of research at Schaeffer's Investment Research.
The analyst said he remained "extremely bullish," on stocks in the medium and long-term, but cautioned that a pullback may lie ahead in coming days after the year's strong gains.
Discount retailers rose Wednesday. Dollar Tree jumped $4.31, or 11 percent, to $45.39 after reporting a 22 percent profit increase. Dollar General also rose $1.61, or 3.6 percent, to $46.56. Family Dollar Stores rose $1.39, or 2.5 percent, to $57.68.
The yield on the 10-year Treasury note rose two basis points to 1.90 percent.
Among other stocks making big moves;
- Priceline.com rose $17.42 to $695.91 after reporting that its net income jumped in the fourth quarter as bookings grew.
- First Solar plunged $4.32, or 13.8 percent, to $27.04 after the company posted disappointing sales for the fourth quarter and gave a weak early outlook for the year.
- Target fell 93 cents, or 1.5 percent, to $63.12 after the No. 2 discount chain's quarterly income fell 2 percent as it dealt with intense competition during the holiday shopping season.
- DreamWorks Animation fell 30 cents, or 1.8 percent, to $16.31 after posting a loss of $82.7 million. The company booked a write-off on its November release "Rise of the Guardians" and on an upcoming movie that needs to be reworked.


text:
Mother Nature|Furrow
A single unit is a half yard. e.g., selecting one for a half yard, two for one yard, 4 for 2 yards, etc. All yardages are cut in continuous length when multiples are ordered.
CARE INSTRUCTIONS: Hand wash is recommended with mild, bleach-free detergent and hang-dry all cotton fabrics for best results. If machine washed, please use cold water with like colors on a gentle cycle. Dry on low-heat tumble setting to minimize shrinkage.
Content: 100% Organic Cotton
Designer: Leah Duncan
Collection: Furrow
Width: 44/45″
Weight Per Yard: 5.5 oz


text:
[1] – September 28, 2013 "The Skeptics™" Burzynski discussion: By Bob Blaskiewicz – 2:19:51
BB – Bob Blaskiewicz
DJT – Didymus Judas Thomas
BB – "Ummm, o-kay"
"Uh, I want to turn this over to the people who are watching"
"Um, I want to give them a a chance to address you as well"
"Uhmmm, hi everyone"
BB – "A every time that I and and and and, and David (James @StortSkeptic the Skeptic Canary) points this out, that um, you you know you're not going to speculate about the the FDA but then at every turn you're invoking the FDA as being obstructionist"
BB – "I, I just find that to be contradictory and and self-defeating"
DJT – Bob, exactly where did I invoke "the FDA as being obstructionist" ?
BB – "Um, it's it's it's not the FDA's, but you understand it's not the FDA's job to tell someone that their drug doesn't work"
BB – "it's it's it's up to Burzynski"
"It's up to Burzynski to show that his drug does work"
"And it's always been his burden of proof"
"He's the one that's been claiming this miracle cancer cure, forever"
DJT – Bob, Burzynski showed and proved what he needed to prove to the FDA in order to do phase 2 clinical trials, 9/3/2004 – FDA granted "orphan drug designation" ("ODD") for Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma, .10/30/2008 – FDA granted "orphan drug designation" ("ODD") for Antineoplastons (A10 and AS2-1 Antineoplaston) for treatment of gliomas, and FDA approved phase 3 [1-2]
Oh, and Bob, exactly when did Burzynski 1st claim "this miracle cancer cure" ?
BB – "Um, that we'd love to see, however we can't see, however we can't see it because of proti protri proprietary uh protections that the FDA is giving to Burzynski, right ?"
"They're not sharing his trial designs because they are his trial designs, right ?"
"That the makeup of his drug that he's distributing are his, uh design, and his intellectual property"
"So the FDA is protecting him, uh from outside scrutiny"
DJT – Bob, you make it sound like it's part of some grand "conspiracy" between Burzynski and the FDA to keep information from "The Skeptics™" [3]
Subpart F–Confidentiality of Information
Sec. 601.50
Confidentiality of data and information in an investigational new drug notice for a biological product
(a) The existence of an IND notice for a biological product will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged
BB – "While you may imagine that that, that that the FDA is is somehow antagonistic toward him"
"They've given him every opportunity, over 60 opportunities to prove himself worth uh their confidence and hasn't"
DJT – Bob, that certainly explains the 9/3/2004 and .10/30/2008 ODD's and phase 3 clinical trial approvals by the FDA – NOT [1-2]
BB – "I don't, the thing is though that, that that's a inver, shifting the burden of proof off of Burzynski"
"Burzynski has to prove them wrong, has to prove him right"
"The FDA is not there to say this doesn't work"
DJT – Bob, who initiated and put into place the clinical trial hold ?
Burzynski ?
Both ?
BB – "So, I mean, honestly, um, saying "Well, when the F, FDA tells you that it doesn't work, the FDA's never gonna say that because that's not their job"
BB – "That's not an option, because they're never gonna do it"
"They relinquish, a lot of authority, over to Burzynski, and his Institutional Review Board, which, I would mention, has failed 3 reviews in a row"
Bob, where are the "final reports" for those "3 reviews" ?
BB – "Right ?"
"It is Burzynski's job to be convincing"
"It is not our uh, uh, it it it he hasn't produced in decades"
"In decades"
"In hundreds and hundreds of patients, who've payed to be on this"
"Hell, we'd we'd we'd like a prelim, well when you're talking about something that is so difficult as brainstem glioma, that type of thing gets, really does in the publishing stream get fast-tracked there"
DJT – Bob, Burzynski has provided numerous phase 2 clinical trial preliminary reports, which our #fave oncologist has chosen to ignore [4]
BB – "they test it"
"Yeah, and they they they want uh, that was evidence of fast-tracking is what, that rejection was uh e was very quickly"
DJT – Bob, have you checked The Lancet Oncology [5] to see what was so much more important than Burzynski's "phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results" [6] and the Japanese antineoplaston study ? [7]
BB – "So, how long will it be before Burzynski doesn't publish, that you decide that uh perhaps he's he's, doesn't have the goods ?"
"Um, so, uh, uh again, the FDA is not the arbiter of this"
"It's ultimately Burzynski"
"You've been speculating about what the FDA's motivation are like crazy"
"Why not speculate about Burzynski a little bit"
DJT – Well, how have I been speculating ?
BB – "Well actually I'm not even asking you to speculate about Burzynski, I'm only asking you to tell me, how long would it take, uh how, for him to go unpublished like this, um, for this long, before you would doubt it ?"
DJT – Note how, above, without proving it, Bob claimed "at every turn you're invoking the FDA as being obstructionist", and now, directly above, again, without proving it, Bob claims "You've been speculating about what the FDA's motivation are like crazy"
DJT – what the journals keep saying, in response
BB – "What ?"
DJT – You know, are they going to give The Lancet response, like they did in 2 hours and such, saying, "Well, we think your message would be best heard elsewhere," or they gonna gonna give The Lancet response of, "Well, we don't have room in our publication this time, well, because we're full up, so, try and pick another place" ?
BB – "But these but but but that doesn't have any bearing on"
"That doesn't"
"Oh I'm not asking you how long, how long, would it take you for you to start doubting whether or not he has the goods ?"
"How long would it take ?"
"It's a it's a it's a question that should be answered by a number uh uh months ?"
"Years ?"
"How long ?"
"It's been 15 years already"
DJT – Well, you like to jump up and down with the "15 year" quote, but then again I always get back to, Hey, it's when, when the report, when the clinical trial is done
DJT – Not that he's been practicing medicine medicine for 36 years, or whatever, it's when the clin, clinical trial was done
BB – "I could push it back to 36 years"
"He hasn't shown that it works for 36 years"
"I can do that"
"I was being nice"
DJT – Note how Bob acts like he's been hit with "The Stupid Stick"
If he wants to go back "36 years", I can refer back to 1991 (11/15/1991) – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a 1 page Memorandum Re:
Antineoplaston to Decision Network, which advised, in part:
"It was the opinion of the site visit team that antitumor activity was documented in this best case series and that the conduct of Phase II trials was indicated to determine the response rate" [8]
DJT – The FDA A believes there is evidence of efficacy
BB – "Perhaps based on bad phase 2"
DJT – Well, we don't know that
We don't have the Freedom of Information Act information
DJT – Remember, Bob is the one who told me during the 9/28/2013 Google+ Burzynski Discussion Hangout:
"You're you're you're assuming"
"You're you're you're assuming that"
"You're assuming that"
"Um, I'm not assuming that"
"There is a correct answer here"
"You don't know"
"You don't know"
"You need to look into it"
"Alright ?"
"Before you dismiss it you have to look into it"
"Everytime somebody throws uh uh something to me,
I have to look into it"
"That's just, it's my responsibility as a reader"
"T t and what I would honestly expect and hope, is that you would be honest about this, to yourself, and and and that's the thing we don't, we often don't realize that we're not being honest with ourself"
"I try to fight against it, constantly"
Bob just ASSUMED that the FDA approved phase 3 clinical trials for Burzynski "Perhaps based on bad phase 2", but tells me NOT to ASSUME ?
BB – "He withdrew"
"He withdrew the the phase 3 clinical trial"
"I that before recruiting,
although I've seen lots of people say they were on a phase 3 clinical trial"
"I wonder how that happened"
DJT – Well, we know what happened in the movie because Eric particularly covered that when they tried to get what, what, was it 200 or 300 something institutions to take on a phase 3, and they refused
BB – "Uh did do do you think that if they thought that he was a real doctor that they all would have refused like that ?"
DJT – Well, Eric gave the reasons that they said they would not take a particular uh phase 3
And so using that excuse that you you just gave there, I'm not even gonna buy that one, because that's not one of the reasons
Note how Bob pulls out the old "if they thought that he was a real doctor" line ?
Is Bob now claiming that Burzynski is NOT even a "real doctor" ?
BB – "He's changed things"
DJT – Eric said they gave
BB – "That The Lancet is a top-tier journal like New England Journal of Medicine"
"It's basically be, besieged by uh 100′s of people submitting their, their, their reports"
"Um, it's just, you know, let's say he, someone has such a thin publishing record as Burzynski does, do you think that it's likely that he will ever get in a top-tier journal ?"
"What about the the Public Library of Science?"
"It's not the only journal there"
"What about BMC Cancer ?"
"There's lots of places that he can go"
DJT – We'll I'm
BB – "Um, and he doesn't seem to to have evailed himself of that, as far as I can tell"
"And I would know because he'd get rejected, or he'd be crowing, you know"
BB – "Either way, he's gonna tell us what happens"
"He told us what happened with The Lancet, you know"
"I don't have any evidence that suggests to me that he's even trying"
Note how Bob refers to Burzynski's numerous publications as "such a thin publishing record"
Bob, do I need to count all of these for you ? [9]
DJT – Well, I'm, I'm sure that they're going to keep you appraised just like they have in the past, just like Eric has done in the past
I mean, we'll see what happens with the Japanese study [7]
BB – "So let's go back to this"
"How long will it take ?"
"How long will it take before you, the Japanese study's interesting too because we should be able to find that in the Japanese science databases, and we can find, we can't find it at all"
"We can't find it anywhere"
"And, and those are in English, so it's not a language problem"
"We can't find that anywhere"
"We've asked"
"We asked Rick Schiff, for, for that study"
"And, and it hasn't come to us"
"He is now I believe on the Board of Directors, over there"
BB – "He should have access to this"
"We can't get it"
Bob, did you ask:
1. Annals of Oncology 2010;21:viii221 ?
2. European Society for Medical Oncology (ESMO), Colorectal cancer, Abstract: 3558, May 17, 2010 ?
3. Colorectal Cancer Association of Canada, COLORECTAL CANCER RESEARCH, Month Ending June 19, 2009
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets (May 27/09) pg. 5 of 20 ?
4. Kurume University School of Medicine (Japan) Department of Surgery ?
5. Hideaki Tsuda ? [7]
BB – "How how long will it take before you recognize that, nothing is forthcoming ?"
"How long would that take ?"
DJT – Well that's like me asking "How long is it going to take for y'all's, y'all's Skeptics to respond to my questions ?"
Because y'all haven't been forthcoming
BB – "Well, I mean, were talking about a blog here"
"We're talking about life"
"No, we're talking about a blogger's feelings in that case"
"In in this case we're talking about, 1,000′s of patients, over the course of of of generations, you know"
"This is important stuff"
"This is not eh eh equating what's happening to to patients with what's happening to you is is completely off-kilter as far as I can tell"
"It's nothing"
"It's nothing like you not getting to say something on my web-site"
"You know"
"This is they they have thrown in with Burzynski, and they've trusted him, and he's produced nothing"
"Nothing of substance"
BB – "Nothing that that has made all of that um, uh, n nothing th th th that uh his peers would take seriously"
"The other thing that that that strikes me now is that, you know, you you you you keep saying that, well Eric is going to to share things with you"
"Does it ever concern you eh uh eh occur to you that Eric might not be reliable ?"
Bob, do you want to have a contest to determine which of you is more "reliable" ?
DJT – Well, he gave you The Lancet information and he posted the e-mail in the movie, and Josephine Jones posted a copy of it [6]
BB – "He then, and then he"
"And then he he, you know, the the the the dialogue that sprung up around that was, well see, he's never going to get to get published"
"Well you're just setting yourself up for wish fulfillment"
"You want him to be, persecuted, so you are ecstatic when he doesn't get to publish, which is unfortunate for all the cancer patients, who really thought that one day, all the studies were going to be published"
DJT – Well, y'all are free to, you know, claim that all you want, because I don't always agree with Eric, and uh, he's free to express his opinion
BB – "Where has Eric been wrong ?"
DJT – Well I don't necessarily believe, what Eric would say about, you know, The Lancet that refused to publish the 2nd one, for the reasons he stated, and which y'all have commented on, including Gorski
You know, I don't necessarily agree with that
I am more agreeable to y'all, saying that, you know, they're busy, they've got other things to do, but I'm kind of still laughing at their 1st response which he showed in the movie about how they felt about, you know his results would be better in some other publication
I thought that was kind of a ridiculous response to give someone
BB – "It's it's it's it's a form letter"
"You know"
"They're just saying, "No thanks""
""Thanks, but no thanks" is what they were saying, in the most generic way possible"
"Like I said, they're besieged by researchers trying to publish"
DJT – Well you would think that if its a form letter they would use the same form that they used the 2nd time
You know, they didn't use the same wording that they used the 1st time
I would have think that, you know, their 2nd comment
BB – "So, so, possibly"
"So possibly what you are saying is that they in fact have read it, and after having read it they've rejected it"
"Is that what you're saying ?"
"Because that's what peer-review is"
DJT – Nah, I'm not saying that they did that all
I'm just sayin', you know, that they gave, 2 different responses, and I would think that the 2nd one they gave
BB – "Do you know it was the same editor, that it came from the same desk ?"
"You can't make that assumption that that the form letter will be the same form letter every time"
"I mean you just can't"
"I mean in in some ways we have a lot of non-information that you're filling in, with what you expect, as as opposed to what's actually really there, and I I I just think you're putting too much uh stock in one uh, uh, in in in in this uh the publication kerfuffle"
BB – "Um"
DJT – Well I find it funny, something along the lines of, you know, "We believe your message would be received better elsewhere, you know
I don't see that as a normal response, a scientific publication would send to someone trying to publish something
I mean, to me that sounds, like, if you're doing that, and you're The Lancet Oncology, maybe you need to set some different procedures in place, 'cuz you would think that with such a great scientific peer-reviewed magazine, that they would have structured things in as far as how they do their operations
BB – "Well, not necessarily"
"I've been in any # of professional groups where the organization is just not optimal, and publications certainly th there are all sorts of pressures from all sorts of different places"
BB – "I I have no problems whatsoever with seeing that this might not be completely uh um uh streamlining uniform processes as possible"
"The fact that it's not uniform, doesn't have anything to do with Burzynski not publishing, not producing good data"
"Not just going to a, you know, god, even if, even if, let's put it this way, even if he went to a pay to play type publication where you have to pay in order to get your manuscript accepted; and he has the money to do this, it wouldn't take that much, and he were to put out a good protocol, and he were to show us his data, and he would make his, his his stuff accessible to us, then we could validate it, then we could look at it and say, "Yeah, this is good," or "No, this is the problem, you have to go back and you have to fix this""
"Right ?"
"So we really, every time we talk about the letter that he got, yeah that doesn't have much to do with anything, really"
BB – "We wanna see the frickin' data"
"And if he had a cure for some cancers that otherwise don't have reliable treatments, he has an obligation to get that out there anyway he can"
"And if if peer-review doesn't, you know, play a, if peer-review can't do it, you know, isn't fast enough for him, then he should take it to the web, and he should send copies out to every pediatric, uh, you know, oncologist that there is"
"That's the way to do it"
DJT – Well, I'm sure, I'm sure Gorski would have a comment about that, as he's commented previously about how he thinks uh Burzynskishould publish
BB – "It's the, it's the data itself"
"If if Burzynski is is, is confident in his data, he will put it out there"
"Right ?"
"One way or the other"
DJT – Like I said before
Like I said before on my blog, you know, even if Burzynski publishes his phase 2 information, Gorski can just jump up and down and say, "Well, that just shows evidence of efficacy, you know, it's not phase 3,
so it doesn't really prove it"
DJT – So then he can go on, you know, for however many years he wants to
BB – "Um, almost no treatment goes out without trials"
"Massive amounts of data are required"
Bob, do you think that's the 2.5 million pages of clinical trial data that Fabio said Burzynski sent to the FDA ? [10]
BB – "Uh, in in in that sense, you know, uh all the the the, you know, kind of back-peddling and and and trying to defend him is is going to, not going to help his case at all"
Bob, exactly where did I exhibit any "kind of back-peddling" ?
BB – "You are, honestly as far as I can tell you are doing the um, you know, you're you're ah throwing up uh, uh, uh, you're giving me another uh invisible dragon in the garage, um"
DJT – Well y'all, y'all can call things what y'all want
I mean, y'all can give these, fallacy arguments and all that garbage that y'all like, because that's what y'all like to talk about instead of dealing with the issues
I mean, Gorski doesn't want to deal with the issues
BB – "Okay, so"
"What you're telling me is that you trust the FDA to to be able to tell you when he's not doing, good science, but also that you don't trust the FDA"
"Do you see an inherent conflict there ?"
DJT – How did I say I, I didn't trust them ?
BB – "Well, when I, whenever I would ask about, like, why would these trials aren't happening uh and, you know, you say well the the FDA's arranged it"
"The FDA's in control"
"They sign off on these things"
"But they're they're they're they're at the same that they're, they're trustworthy they're also not trustworthy depending on what you need for the particular argument at the time"
BB – "You're suggesting that they're untrustworthy"
DJT – No, I'm just sayin' that I've raised questions and none of The Skeptics wanna to uh talk about 'em [11]
BB – "Do you know that the FDA pulled out of the prosecution ?"
"Did you know that the FDA pulled out of the prosecution um of his criminal case, because they were backing a researcher ?"
Bob, would that "researcher" be Dvorit D. Samid, who was in Burzynski: Cancer is Serious Business (Part I) ?
DJT – Well, we know a lot stuff they did, but that still doesn't impress me that they pulled out of the prosecution
I mean
BB – "Yeah, the the the it wasn't the FDA who was pressing charges, it was a Federal prosecutor"
DJT – Right
BB – "Right"
"And and, they declined to provide information that the prosecution needed"
"That's important"
"That that that's really important"
"That he has been given the benefit of the doubt, and he has come up wanting, for decades now"
DJT – Well I find it interesting a lot of this uh, a lot of these letters that were provided between, you know, the government and Burzynski, when the uh phase 2 study was going on, at the behest of the NCI
You know, anybody who reads that stuff knows, that when you just ignore the person that's been doing, do treating their patients for 20 something years, or close to 20 years, and you change the protocol without his approval, and you don't use the drugs in the manner that he knows works
BB – "One of the interesting things about Doubting Thomas that I think you should definitely consider for yourself, is that at some point, when faced with the real opportunity to prove or disprove his assertions, he doubted himself"
"And that's important"
"And that's where you're falling short in the analogy"
DJT – Well, I think The Skeptics, Skeptics are falling short because, you know, they don't own up to
BB – "I've laid out exactly what it would take for me to turn on a fucking dime"
"I have, I have made it abundantly clear what I need"
"Gorski has made it abundantly clear"
"Everybody else, Guy, and David, and Josephine Jones, uh, the Morgans, all of them have made it abundantly clear, what it would take to change our minds, and you've never done that"
BB – "And even in this, this was an opportunity to do that"
"To come up with a basis for understanding, where it's like, you know what, If we can show this, you know, if we can show a this guy, that, that, there, that his standards are not being met, then, you know, we could possibly have some sort of ongoing dialogue after this"
DJT – So I can say that since the Mayo Clinic (Correction: M.D. Anderson) finished their study in 2006, and it took them until 2013, to actually publish it, then I can say, well, Burzynski finished his in 2009, which was 3 years later, which would give Burzynski until 2016
BB – "Why wasn't that study"
DJT – for me to make up my mind (laughing)
BB – "Why wasn't that, that that that, still . . again, it it doesn't seem really to to approach the the the, main question here"
"You know, um . . what are the standards that you have that it isn't, what are your standards to show that it isn't efficacious ?"
DJT – Well I can say, well I'm going to have to wait, the same amount of time I had to wait for Mayo (Correction: M.D. Anderson) to publish their study; which was from 2006 to 2013
BB – "Why was the Mayo"
"Why was the Mayo (Correction: M.D. Anderson) study delayed ?"
Note how Bob ASSUMES that the publishing of the final results of the M.D. Anderson study were delayed
DJT – How do you know it was delayed ?
BB – "Well you said you had so many years before you finish it and go in"
DJT – I mean, has anybody
BB – "Why, why did it take so long ?"
DJT – done a review of when a clinical trial is studied, and completed, and how long it took the people to publish it ?
You know
If they could point to me a study that's done that, and say, well here's the high end, here's the low end of the spectrum, here's the middle
BB – "I have something for you, okay ?"
"Send me that"
"Could you send me that study the way that it was published because um, just just send me the final study, um, to my e-mail address"
DJT – Sure
BB – "Um, because, I can ask that question of those researchers, why was this study in this time, and what happened in-between"
BB – "Why did it take so long for it, for it to come out"
DJT – Sure, but that's not gonna, you know like, answer an overall question of, you know, somebody did a comparative study of all clinical trials, and, when they were finished, and at, and when the study was actually published afterwards
You know, that's only gonna be one, particular clinical study
BB – "Right"
"Um, but it it would, perhaps, answer the question; because you're using it as an example on the basis of which to dismiss criticism, whether or not, uh, it is the standard, and therefor you're allowed to accept that Burzynski hasn't published until 2016, or, um, it's an anomaly, which is also a possibility, that most stuff comes out more quickly"
DJT – Well, we know that the Declaration of Helsinki doesn't even give a standard saying, "You must publish within x amount of years," you know ?
So, I've yet to find a Skeptic who posted something that said, "Here are the standards, published here"
BB – "I I, yeah, the other thing that David James points out is you know, why 2016 when he's had 36 years already ?"
DJT – Again, we get back to, when the clinical trial is finished, not when Burzynski started
BB – "Treating people"
DJT – I mean, you would expect to find a results to be published after, the final results are in
BB – "You would expect the Burzynski Patient Group to be a lot bigger after 36 years, and in fact is
DJT – You would expect some people would want to have confidentiality, and maybe not want to be included
BB – "So, if you're unsure about this stuff, if you're unsure about the the time to publication, why are you defending it so hard, other than saying, "I don't know, I really need to"
DJT – Why am I unsure ?
BB – "Uh about the
DJT – (laughing) I just gave you an example
BB – "The reasons, the reasons for which that he's, no, why are you defending him so hard, when you're unsure ?
DJT – Oh, who said I was unsure ?
I just gave you an example
Note how Bob ASSUMES that I'm "unsure" when I had the same answer since 0:32:07 [12]
Bob, who approves "Accelerated Approval" ?
2. A peer-reviewed scientific journal ?
3. The Skeptics™ ?
Bob, It's your unlucky [13]
[1] – September 28, 2013 "The Skeptics™" Burzynski discussion: By Bob Blaskiewicz – 2:19:51
[2] – FDA grants Orphan Drug Designation (ODD) for A10 and AS2-1:
Click to access PressRelease_12022008_BZYR(2).pdf
josephinejones (@_JosephineJones), D Nile ist http://josephinejones.wordpress.com/2013/01/23/happy-birthday-dr-burzynski-and-goodbye-antineoplastons/comment-page-1/#comment-8921
[3] – The Skeptics @Majikthyse reveals madjik research skilz:
[4] – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
[5] – The Lancet Oncology
[6] – FINALLY, one of "The Skeptics™" has the "Balls" to do what even Dr. David H. "Orac" Gorski would NOT do:
[7] – Burzynski – The Antineoplaston Randomized Japan Phase II Clinical Trial Study:
[8] – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet "fact sheet":
[9] – Stanislaw Rajmund Burzynski Publications:
[10] – Critiquing: In which the latest movie about Stanislaw Burzynski "cancer cure" is reviewed…with Insolence:
[11] – QUESTIONS the Critics and Cynics, "The Skeptics™" do NOT want to ANSWER:
[12] – The Biggest Loser: "The Skeptics™" Guy Chapman (guychapman @vGuyUK @SceptiGuy) http://www.chapmancentral.co.uk/blahg/ – September 28, 2013 "The Skeptics™" Burzynski discussion: By Bob Blaskiewicz – 2:19:51
[13] – Burzynski: Why has the FDA NOT granted Accelerated Approval for Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) ?:


text:
Today's News: Our Take - Lifetime Axes Drop Dead Diva After Four Seasons
Drop Dead Diva is dead... at Lifetime, which has canceled the series after four years, Deadline reports.
Drop Dead Diva told the story of a shallow model (Brooke D'Orsay) who dies and is brought back to life as an overweight, do-gooder lawyer (Brooke Elliot). According to Deadline, Lifetime felt the dramedy did not fit in with its move toward edgier material.
Fall 2013 TV scorecard: Which shows are returning? Which aren't?
After premiering to 2.8 million viewers in July 2009, its most recent season averaged a little more than 2 million viewers.
Sony Pictures TV, which produces Drop Dead Diva, might possibly shop it elsewhere. The news comes as another Lifetime scripted series, Army Wives, is undergoing several cast changes for the upcoming seventh season.
Will you miss Drop Dead Diva?
View original Lifetime Axes Drop Dead Diva After Four Seasons at TVGuide.com
Related Articles on TVGuide.com
Other Links From TVGuide.com